Global Custom Market Research Reports Provider Company

phone

Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review

  • Published Date: 24 Oct 2018
  • Number of Pages: 63
  • Category: SWOT Analysis
  • Country: United States of America
Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Exelixis Inc (Exelixis) is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma; and Cotellic (cobimetinib) is developed in combination with vemurafenib for the treatment of patients with mutation-positive advanced melanoma. The company also enters into collaborative partnerships with pharmaceutical and biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in South San Francisco, California, the US.

Exelixis Inc Key Recent Developments

Oct 08,2018 Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress
Sep 21,2018 TOPC : Exelixis Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma[Newswire : Healthcare-BW]
Sep 19,2018 TOPC : Exelixis Partner Ipsen Announces Health Canadas Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma[Newswire : Healthcare-BW]
Aug 01,2018 Exelixis announces second quarter 2018 financial results and provides corporate update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData


List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Exelixis Inc - Key Facts 6
Exelixis Inc - Key Employees 7
Exelixis Inc - Key Employee Biographies 8
Exelixis Inc - Major Products and Services 9
Exelixis Inc - History 10
Exelixis Inc - Company Statement 13
Exelixis Inc - Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 Company Analysis 16
Company Overview 16
Exelixis Inc - Business Description 17
Exelixis Inc - Corporate Strategy 18
Exelixis Inc - SWOT Analysis 19
SWOT Analysis - Overview 19
Exelixis Inc - Strengths 19
Exelixis Inc - Weaknesses 20
Exelixis Inc - Opportunities 21
Exelixis Inc - Threats 22
Exelixis Inc - Key Competitors 23
Section 3 Company Financial Ratios 24
Financial Ratios - Capital Market Ratios 24
Financial Ratios - Annual Ratios 25
Performance Chart 27
Financial Performance 27
Financial Ratios - Interim Ratios 28
Financial Ratios - Ratio Charts 29
Section 4 Companys Lifesciences Financial Deals and Alliances 30
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
Exelixis Inc, Recent Deals Summary 32
Section 5 Companys Recent Developments 33
Oct 08, 2018: Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress 33
Oct 08, 2018: Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress 39
Sep 21, 2018: TOPC : Exelixis Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma[Newswire : Healthcare-BW] 46
Sep 19, 2018: TOPC : Exelixis Partner Ipsen Announces Health Canadas Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma[Newswire : Healthcare-BW] 48
Sep 19, 2018: TOPC : Exelixis Partner Ipsen Announces Health Canadas Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma[Newswire : Healthcare-BW] 49
Sep 19, 2018: TOPC : Exelixis Partner Ipsen Announces Health Canadas Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma[Newswire : Healthcare-BW] 50
Aug 01, 2018: Exelixis announces second quarter 2018 financial results and provides corporate update 51
May 22, 2018: Exelixis Appoints Andrew R. Peters to Newly Created Position of Vice President, Strategy 54
Apr 09, 2018: Exelixis Elects Dr. Maria Freire to Its Board of Directors 55
Nov 01, 2017: Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update 56
Section 6 Appendix 59
Methodology 59
Ratio Definitions 59
About GlobalData 63
Contact Us 63
Disclaimer 63

List Of Tables


Exelixis Inc, Key Facts 6
Exelixis Inc, Key Employees 7
Exelixis Inc, Key Employee Biographies 8
Exelixis Inc, Major Products and Services 9
Exelixis Inc, History 10
Exelixis Inc, Subsidiaries 15
Exelixis Inc, Key Competitors 23
Exelixis Inc, Ratios based on current share price 24
Exelixis Inc, Annual Ratios 25
Exelixis Inc, Annual Ratios (Cont...1) 26
Exelixis Inc, Interim Ratios 28
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31
Exelixis Inc, Recent Deals Summary 32
Currency Codes 59
Capital Market Ratios 59
Equity Ratios 60
Profitability Ratios 60
Cost Ratios 61
Liquidity Ratios 61
Leverage Ratios 62
Efficiency Ratios 62

List Of Figures


Exelixis Inc, Performance Chart (2013 - 2017) 27
Exelixis Inc, Ratio Charts 29
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30
Exelixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 31

Yasuhara Chemical Co Ltd (4957) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

View Report

NARI Technology Development Co Ltd (600406) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been

View Report

Huons Global Co Ltd (084110) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports